← All trials
NCT04351932
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2020
- Primary completion
- Jun 7, 2021
- Completion date
- Sep 7, 2021
- First posted
- Apr 17, 2020
- Last posted
- Apr 17, 2020
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Catolica Santiago de GuayaquilLead sponsor
- Maastricht UniversityCollaborator
- Universidad Catolica Santiago de GuayaquilReponsible party - principal investigator
- Universidad Catolica Santiago de GuayaquilOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.